Evidence map›Paper›PMID 19552750›Full record

Trial reportBritish journal of clinical pharmacology2009

Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus.

Nadia Rashid Al Mazroui, Mostafa Mohamed Kamal, Naserdeen Mehana Ghabash, Targ Ahmed Yacout, Prashant Laxman Kole, James C McElnay

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pharmacist services for non-hospitalised patients.The Cochrane database of systematic reviews · 2018
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Interventions for enhancing medication adherence.The Cochrane database of systematic reviews · 2014
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Patient-Centered Outcomes of Medication Adherence Interventions: Systematic Review and Meta-Analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
    Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nadia Rashid Al MazrouiDepartment of Pharmacy, Sheikh Zayed Military Hospital, Abu Dhabi, UAE.
Mostafa Mohamed Kamal
Naserdeen Mehana Ghabash
Targ Ahmed Yacout
Prashant Laxman Kole
James C McElnay

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo examine the influence of a pharmaceutical care programme on disease control and health-related quality of life in Type 2 diabetes patients in the United Arab Emirates.

methodsA total of 240 Type 2 diabetes patients were recruited into a randomized, controlled, prospective clinical trial with a 12-month follow-up. A range of clinical measures, medication adherence and health-related quality of life (Short Form 36) were evaluated at baseline and up to 12 months. Intervention group patients received pharmaceutical care from a clinical pharmacist, whereas control group patients received their usual care from medical and nursing staff. The primary outcome measure was change in HbA(1c). British National Formulary and Framingham scoring methods were used to estimate changes in 10-year coronary heart disease risk scores in all patients.

resultsA total of 234 patients completed the study. Significant reductions (P < 0.001) in mean values (baseline vs. 12 months; 95% confidence interval) of HbA(1c)[8.5% (8.3, 8.7) vs. 6.9% (6.7, 7.1)], systolic [131.4 mmHg (128.1, 134.7) vs. 127.2 mmHg (124.4, 130.1)] and diastolic blood pressure [85.2 mmHg (83.5, 86.8) vs. 76.3 mmHg (74.9, 77.7)] were observed in the intervention group; no significant changes were noted in the control group. The mean Framingham risk prediction score in the intervention group was 10.56% (9.7, 11.4) at baseline; this decreased to 7.7% (6.9, 8.5) (P < 0.001) at 12 months but remained unchanged in the control group.

conclusionsThe pharmaceutical care programme resulted in better glycaemic control and reduced cardiovascular risk scores in Type 2 diabetes patients over a 12-month period.

Indexed as

AdultAgedAged, 80 and overBlood GlucoseDiabetes Mellitus, Type 2Diabetic AngiopathiesFemaleFollow-Up StudiesGlycated HemoglobinHumansHypoglycemic AgentsMaleMedication AdherenceMiddle AgedOutcome Assessment, Health CarePatient Education as TopicBlood GlucoseGlycated HemoglobinHypoglycemic Agents

Identifiers

PMID19552750
PMCPMC2686072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.